Pursuant to the fourth enactment clause of House Bill 2079 passed during the 2021 General Assembly Session, the Board of Pharmacy convened a work group on August 16, 2021 to develop recommendations for possible statewide protocols for pharmacists to initiate treatment for tobacco cessation and conditions for which CLIA-waived tests may be used to guide clinical diagnosis and treatment, including influenza, Group A Streptococcus, and urinary tract infections. Motions regarding recommendations for statewide protocols for tobacco cessation, Group A Streptococcus, and urinary tract infections failed and therefore, no recommendations resulted. A motion to not recommend a statewide protocol for treating influenza passed 3:1.

Work Group Members:

Kris Ratliff, DPh
Work Group Chairman
Board of Pharmacy member*

Sarah Melton, PharmD
Board of Pharmacy member*

Jacob Miller, D.O.
Board of Medicine member*

Brenda Stokes, M.D.
Board of Medicine member*

Laurie Forlano, D.O., MPH
Deputy Director, Office of Epidemiology, Virginia Department of Health

Will Hockaday
Tobacco Control Program/Outreach Coordinator, Virginia Department of Health

Kristin Collins, MPH
Policy Analyst, Office of Epidemiology, Virginia Department of Health

Kelly Goode, PharmD, BCPS, FAPhA, FCCP
Virginia Commonwealth University School of Pharmacy

Iain Pritchard, PharmD, BCACP
Shenandoah University, Bernard J. Dunn School of Pharmacy

Zahra Raza, M.D.
Virginia Commonwealth University School of Pharmacy

John R. Lucas, D.O.
Edward Via College of Osteopathic Medicine

Michelle Thomas, PharmD, CDE, BCACP
Virginia Pharmacists Association

Wendy Klein, M.D.
Medical Society of Virginia

*Voting members